Sad news that Henry Wendt III passed away earlier this month. He was CEO of Smithkline until 1994, then became an investor. I had the pleasure of working with him at Caxton in 2004-2005 for brief but memorable period. Great leader & true gentleman. RIP.
legacy.com/us/obituaries/…

$XBI has tumbled ~15% from it's Feb high... and so goes the 2024 IPO class performance: 7 out of 8 VC-backed biotech IPOs are now trading below their offer price.
Risk-on #biotech stocks have trouble fighting negative interest rate sentiment and sector outflows; cycle needs to

'Deconstructing the Diligence Process: An Approach to Vetting New Product Theses'

Atlas' Aimee Raleigh opines in a fantastic new blog covering:
- Target Validation
- Directionality and Druggability
- Pharmacology
- Path to PoC
- Product Opportunity

lifescivc.com/2024/04/decons…

Next gen delivery solutions are the key for enabling novel gene modification modalities...

'Nvelop launches with $100M, advancing David Liu, Keith Joung gene editing delivery work'

endpts.com/nvelop-launche…

First disclosure of our STAT3 degrader KT-333 and its biochemical mechanism of action. This presentation highlights how we select the right E3 for each target and our sophisticated ternary complex characterization including cryo EM studies. Great work from the Kymera Therapeutics team!

'We beat big pharma': Biden applauds the Innovation Reduction Act, calls for a further reduction in R&D spending for new innovative medicines

endpts.com/we-beat-big-ph…

Merck's MK-0616 originated from collaboration with Ra Pharma, a macrocycle company based on mRNA display co-founded by Nobel Laureate Dr. Jack Szostak...

Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development. Obsidian Therapeutics #TILs

obsidiantx.com/news-releases/…

An incredible day for Diagonal Therapeutics as they launch with $128M in financing to discover and develop agonist antibodies to tackle the underlying causes of rare diseases.

globenewswire.com/news-release/2…

We are delighted to share the #Science2Startup class of 2024!

This year’s 8 scientific presenters were selected by an advisory group of experienced #biotech investors to present their #startup ideas on April 10th at the Broad Institute.

Learn more: science2startup.com

“Lessons From A Private Funding Round: Science, Relationships, And Experience”

Reflections from sionna_tx CEO Mike Cloonan on their recent Series C financing - new From the Trenches blog post

lifescivc.com/2024/04/lesson…

😂😂😂

Fun and thought-provoking list of Pharma/R&D questions (and some data) to skim through...

Thx Frank S. David for sharing.

Devastated. A supreme scientific mentor, R&D leader and a true giant of our industry. Learnt so much over the past 29 years at his feet on ‘doing the killer experiment’ ‘show me the data’ ’the world belongs to finishers’. Bruce Booth John Maraganore 🇺🇦🇮🇱

Hear my conversation on the state of play in Biotech, with @lifescivc Bruce Booth - always an interesting conversation. Here, open access on @youTube. Biotech Benefiting from Belt-Tightening youtu.be/z5R4SUI5kns?si… via YouTube

. Atlas Venture's Bruce Booth sees biotech's belt-tightening starting to yield more favorable financing environment, but there's still pain to come. + how new modalities will play out. Watch Bruce Booth in conversation BioCentury's Simone Fishburn youtu.be/z5R4SUI5kns

A new understanding of Alzheimer’s disease suggests we have overlooked an important possible cause of the condition - a build-up of fat droplets in brain cells. newscientist.com/article/242209…

While I hate TikTok as a parent, this ban strikes me as an egregious removal of free speech rights and scary concentration of authoritative coercive power into gov't hands... banning websites/apps... All done under the guise of national security... Be wary, very wary...